Ameliorative effects of Helianthus annuus against nephrotoxic, cardiac, and haematological disorders in alloxan-induced hyperglycaemia in albino rats
Online veröffentlicht: 23. Okt. 2018
Seitenbereich: 371 - 377
Eingereicht: 27. Apr. 2018
Akzeptiert: 17. Sept. 2018
DOI: https://doi.org/10.2478/jvetres-2018-0053
Schlüsselwörter
© 2018 S.O. Onoja et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
The development and progression of diabetes and its complication are linked to chronic inflammatory conditions. Increased expressions of systemic inflammatory markers are associated with the pathogenesis of insulin resistance and type 2 diabetes (12). Macro- and microvascular complications of diabetes are mediated by inflammatory processes, thus prevention or treatment of inflammation will inhibit, retrogress, and/or ameliorate the complications of diabetes mellitus (DM) (14). Most antidiabetic drugs have been reported to possess anti-inflammatory properties (29).
One of the most frequent complications of DM in both humans and experimental animals is diabetic nephropathy (DN). DN develops as a result of non-enzymatic glycation of protein mediated by hyperglycaemia and reactive oxygen species (ROS) (28). Blood cell dyscrasias such as anaemia and neutrophilia usually co-occur with DN (1). Anaemia in DN and other diseases associated with inflammatory condition are presumed to be caused by reduced iron availability, low erythropoietin, and decrease in life span of red blood cells (RBC) (3). Inflammatory mediators such as cytokines and tumour necrosis factor are in abundance in DN and they accelerate the destruction of RBC precursors and lower the number of erythropoietin receptors in progenitor cells (21). Hypertension is also another cardiovascular complication of DM and often accompanies DN.
The ethnomedical management of DM is evolving rapidly.
All compounds were administered

Effects of HLEHA on body weight (mean ±SEM)
P < 0.05 when compared with 5% tween-20–treated group, SEM – standard error of mean, GLB – glibenclamide, HLEHA – hydromethanol leaf extract of
Effect of HLEHA treatment on erythrocytic profile (mean ±SEM)
Treatment | PCV (%) | HB (g/dL) | RBC (×106/μL) | MCV (fL) | MCH (pg) | MCHC (g/dL) |
---|---|---|---|---|---|---|
5% tween-20, 5 mL/kg | 43.8 ± 1.17 | 15.52 ± 0.56 | 7.81 ± 0.54 | 58.56 ± 3.1 | 20.69 ± 0.97 | 35.4 ± 0.59 |
GLB, 2 mg/kg | 42.6 ± 0.87 | 14.18 ± 0.63 | 7.5 ± 0.25 | 57.31 ± 1.99 | 19.16 ± 1.03 | 33.18 ± 0.74 |
HLEHA, 150 mg/kg | 45.0 ± 0.91 | 14.26 ± 0.57 | 8.21 ± 0.62 | 55.49 ± 3.12 | 17.51 ± 0.69* | 31.48 ± 0.71* |
HLEHA, 300 mg/kg | 44.2 ± 1.11 | 14.88 ± 0.31 | 8.21 ± 0.35 | 54.22 ± 2.54 | 18.29 ± 1.06 | 33.75 ± 1.09 |
HLEHA, 600 mg/kg | 44.13 ± 0.52 | 14.67 ± 0.48 | 7.8 ± 0.62 | 57.45 ± 3.68 | 19.03 ± 0.98 | 33.24 ± 0.84 |
P < 0.05 when compared with 5% tween-20–treated group, SEM – standard error of mean, GLB – glibenclamide, HLEHA – hydromethanol leaf extract of
Effect of HLEHA treatment on leukocytic profile (mean ±SEM)
Treatment | 5% tween-20, 5 mL/kg | GLB 2 mg/kg | HLEHA 150 mg/kg | HLEHA 300 mg/kg | HLEHA 600 mg/kg |
---|---|---|---|---|---|
WBC (x103/mL) | 11.68 ± 0.58 | 9.73 ± 0.43 | 10.89 ± 0.36 | 10.9 ± 0.68 | 9.85 ± 1.26 |
Re neutrophil (%) | 37.0 ± 2.66 | 21.4 ± 1.57* | 28.0 ± 0.53* | 18.0 ± 2.28* | 14.67 ± 1.65* |
Re lymphocyte (%) | 60.0 ± 3.12 | 75.8 ± 1.6* | 68.0 ± 1.31* | 77.67 ± 2.74* | 78.0 ± 2.22* |
Re eosinophil (%) | 0.5 ± 0.19 | 2.4 ± 0.54* | 1.5 ± 0.42 | 2.0 ± 0.37* | 2.67 ± 0.56* |
Re monocytes (%) | 1.75 ±0.49 | 0.2 ± 0.13* | 2.5 ± 0.78 | 1.67 ± 0.42 | 5.67 ± 1.05* |
Re basophils (%) | 0.75 ± 0.31 | 0.2 ± 0.13* | 0.0 ± 0.0* | 0.0 ± 0.0* | 0.0 ± 0.0* |
Ab neutrophil (×103/mL) | 4.43 ± 0.73 | 2.1 ± 0.3* | 3.04 ± 0.12* | 1.87 ± 0.42* | 1.55 ± 0.53* |
Ab lymphocyte (×103/mL) | 6.88 ± 0.13 | 7.37 ± 0.54* | 7.41 ± 0.49* | 7.97 ± 0.91* | 7.55 ± 0.27* |
Ab eosinophil (per mL) | 53.5 ± 20.7 | 219.0 ± 41.92* | 154.75 ± 42.70 | 220.33 ± 53.84* | 244.0 ± 50.21* |
Ab monocytes (per mL) | 220.13 ± 61.98 | 20.2 ± 13.47* | 278.00 ± 84.67 | 170.17 ± 42.23 | 573.17 ± 133.96* |
Ab basophils (per mL) | 92.88 ± 38.73 | 20.2 ± 13.47* | 0.0 ± 0.0* | 0.0 ± 0.0* | 0.0 ± 0.0* |
NLR | 0.64 ± 0.06 | 0.29 ± 0.02* | 0.41 ± 0.01* | 0.24 ± 0.03* | 0.19 ± 0.02* |
P < 0.05 when compared with 5% tween-20–treated group, SEM – standard error of mean, GLB – glibenclamide, HLEHA – hydromethanol leaf extract of
Effect of HLEHA treatment on serum markers of kidney function (mean ± SEM)
Treatment | Urea (mg/dL) | Creatinine (mg/dL) | Urea/creatinine ratio |
---|---|---|---|
5% tween-20, 5 mL/kg | 85.43 ± 1.60 | 1.15 ± 0.03 | 75.26 ± 4.94 |
GLB, 2 mg/kg | 45.19 ± 4.42* | 1.05 ± 0.01 | 43.09 ± 6.15* |
HLEHA, 150 mg/kg | 48.94 ± 4.26* | 1.22 ± 0.03 | 40.91 ± 7.10* |
HLEHA, 300 mg/kg | 53.84 ± 4.01* | 1.08 ± 0.04 | 49.37 ± 3.16* |
HLEHA, 600 mg/kg | 49.69 ± 2.73* | 1.10 ± 0.06 | 47.89 ± 8.42* |
P < 0.05 when compared with 5% tween-20–treated group, SEM – standard error of mean, GLB – glibenclamide, HLEHA – hydromethanol leaf extract of

Photomicrograph of the kidney, H & E, 400×
The V shows congested blood vessel, D shows renal tubular degeneration, G shows the glomerulus and line arrow is pointing at fibroblastic cells. A – 5% tween-20–treated group, B – glibenclamide treated group, C – HLEHA 150 mg/kg treated group, D – HLEHA 300 mg/kg treated group, and E – HLEHA 600 mg/kg treated group

Photomicrograph of the heart muscle, H & E, 400×
The FN shows focal necrosis and H shows hypertrophic muscle fibre in 5% tween-20–treated group. A – 5% tween-20–treated group, B – glibenclamide-treated group, C – HLEHA 150 mg/kg treated group, D – HLEHA 300 mg/kg treated group, and E – HLEHA 600 mg/kg treated group
The ameliorative effects of hydromethanol leaf extract of
The treatment of the rats with GLB and HLEHA reversed weight loss (Fig. 1) and dehydration (Table 3) induced by alloxan. Weight loss in alloxan induced DM is linked to polyuria and muscle wasting as a result of negative protein balance (11). Dehydration in alloxan induced DM is linked solely to polyuria and is associated with hypovolaemia, haemoconcentration (relative polycythaemia), and elevated serum urea and urea : creatinine ratio levels (30, 33). In this study, the serum urea and urea : creatinine ratio levels of GLB and HLEHA-treatment groups were lower (P < 0.05) than the 5% tween-20–treated group (Table 3).
Anaemia and diabetic nephropathy are common complications of both clinical and alloxan-induced DM. The anaemia is attributed to the non-enzymatic glycation of RBC and haemoglobin, and it shortens life-span of RBC as a result of an increased rate of apoptosis (7, 24, 25). Anaemia may also be due to impaired formation of RBC linked to protein glycation (34). Anaemia is also linked to reduced erythropoietin production due to diabetic nephropathy (21). The 5% tween-20–treated group had anaemia which was masked by dehydration-induced relative polycythaemia (2). Aside from anaemia, the haemogram of the 5% tween-20–treated group ought to have been elevated as a result of the dehydration. The absence of any significant (P > 0.05) difference in the erythrocyte profile (PCV, RBC, and HB) of the 5% tween-20– treated group was due to relative polycythaemia (18, 20). The antianaemic activity of HLEHA corroborates the reversal of kidney damage induced by alloxan. This implies that the antianaemic activity of the extract may be attributed to possibly improved erythropoietin production by the kidneys (3).
The treatment of the rats with GLB and HLEHA ameliorated inflammatory and stress responses in the alloxan-induced DM. GLB and HLEHA treatment reduced (P < 0.05) the neutrophil count when compared with 5% tween-20–treated group, while the lymphocyte counts of GLB and HLEHA treated groups were higher (P < 0.05) than the 5% tween-20–treated group (Table 2). The number of circulating neutrophils is elevated in inflammatory conditions, while a decrease in the number of circulating lymphocytes is associated with the stress response in rodents (19). Diabetes mellitus is described as a chronic inflammatory and stressful condition (12). The elevated WBC count in the 5% tween-20–treated group is in agreement with the report of Grossmann
The GLB and HLEHA reversed alloxan-induced DN in the treated rats. Alloxan administration produced elevated serum urea and urea : creatinine ratio (Table 3) as well as the degeneration and fibroplasia of Bowman’s capsule and peritubular spaces (Fig. 2). Alloxan-induced nephrotoxicity is well documented; however, its mechanism is not well understood. The generation of free radicals from the redox cycling of dialuric acid has been proposed to explain the mechanism (28). These free radicals react with cellular substances which include nucleic acid, proteins, and lipids, causing cell damage (24). Although the mechanism of nephroprotective effects of
The cardiac muscles of the 5% tween-20–treated group showed hypertrophy of the fibres and focal degeneration. Hypertrophy of muscle fibre is a characteristic feature of diabetes and chronic kidney disease, especially DN, and is linked to hypertension and anaemia (1). The treatment of the diabetic rats with GLB and HLEHA reversed the histopathologic changes in the heart. This indicates that GLB and HLEHA ameliorate cardiovascular complications associated with diabetes mellitus.
In conclusion, hydromethanol leaf extract of